Search Results - "Williamson, Chris T."

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A by Williamson, Chris T., Miller, Rowan, Pemberton, Helen N., Jones, Samuel E., Campbell, James, Konde, Asha, Badham, Nicholas, Rafiq, Rumana, Brough, Rachel, Gulati, Aditi, Ryan, Colm J., Francis, Jeff, Vermulen, Peter B., Reynolds, Andrew R., Reaper, Philip M., Pollard, John R., Ashworth, Alan, Lord, Christopher J.

“…Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies. Mutations in…”
Get full text

Directing the use of DDR kinase inhibitors in cancer treatment by Brandsma, Inger, Fleuren, Emmy D G, Williamson, Chris T, Lord, Christopher J

“…Defects in the DNA damage response (DDR) drive the development of cancer by fostering DNA mutation but also provide cancer-specific vulnerabilities that can be…”
Get more information

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines by Campbell, James, Ryan, Colm J., Brough, Rachel, Bajrami, Ilirjana, Pemberton, Helen N., Chong, Irene Y., Costa-Cabral, Sara, Frankum, Jessica, Gulati, Aditi, Holme, Harriet, Miller, Rowan, Postel-Vinay, Sophie, Rafiq, Rumana, Wei, Wenbin, Williamson, Chris T., Quigley, David A., Tym, Joe, Al-Lazikani, Bissan, Fenton, Timothy, Natrajan, Rachael, Strauss, Sandra J., Ashworth, Alan, Lord, Christopher J.

“…One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe…”
Get full text

Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers by Dréan, Amy, Williamson, Chris T, Brough, Rachel, Brandsma, Inger, Menon, Malini, Konde, Asha, Garcia-Murillas, Isaac, Pemberton, Helen N, Frankum, Jessica, Rafiq, Rumana, Badham, Nicholas, Campbell, James, Gulati, Aditi, Turner, Nicholas C, Pettitt, Stephen J, Ashworth, Alan, Lord, Christopher J

“…Although PARP inhibitors target - or -mutant tumor cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of…”
Get full text

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors by Williamson, Chris T, Muzik, Huong, Turhan, Ali G, Zamò, Alberto, O'Connor, Mark J, Bebb, D Gwyn, Lees-Miller, Susan P

“…Poly(ADP-ribose) polymerase-1 (PARP-1) inhibition is toxic to cells with mutations in the breast and ovarian cancer susceptibility genes BRCA1 or BRCA2, a…”
Get full text

ATR Is a Therapeutic Target in Synovial Sarcoma by Jones, Samuel E, Fleuren, Emmy D G, Frankum, Jessica, Konde, Asha, Williamson, Chris T, Krastev, Dragomir B, Pemberton, Helen N, Campbell, James, Gulati, Aditi, Elliott, Richard, Menon, Malini, Selfe, Joanna L, Brough, Rachel, Pettitt, Stephen J, Niedzwiedz, Wojciech, van der Graaf, Winette T A, Shipley, Janet, Ashworth, Alan, Lord, Christopher J

“…Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18-SSX fusions, where treatment options are limited. To identify…”
Get full text

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors by Yap, Timothy A, O'Carrigan, Brent, Penney, Marina S, Lim, Joline S, Brown, Jessica S, de Miguel Luken, Maria J, Tunariu, Nina, Perez-Lopez, Raquel, Rodrigues, Daniel Nava, Riisnaes, Ruth, Figueiredo, Ines, Carreira, Suzanne, Hare, Brian, McDermott, Katherine, Khalique, Saira, Williamson, Chris T, Natrajan, Rachael, Pettitt, Stephen J, Lord, Christopher J, Banerji, Udai, Pollard, John, Lopez, Juanita, de Bono, Johann S

“…Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses…”
Get full text

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib by Miller, Rowan E, Brough, Rachel, Bajrami, Ilirjana, Williamson, Chris T, McDade, Simon, Campbell, James, Kigozi, Asha, Rafiq, Rumana, Pemberton, Helen, Natrajan, Rachel, Joel, Josephine, Astley, Holly, Mahoney, Claire, Moore, Jonathan D, Torrance, Chris, Gordan, John D, Webber, James T, Levin, Rebecca S, Shokat, Kevan M, Bandyopadhyay, Sourav, Lord, Christopher J, Ashworth, Alan

“…New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to…”
Get full text

Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells by Lemm, Elizabeth A, Valle-Argos, Beatriz, Smith, Lindsay D, Richter, Johanna, Gebreselassie, Yohannes, Carter, Matthew J, Karolova, Jana, Svaton, Michael, Helman, Karel, Weston-Bell, Nicola J, Karydis, Laura, Williamson, Chris T, Lenz, Georg, Pettigrew, Jeremy, Harwig, Curtis, Stevenson, Freda K, Cragg, Mark, Forconi, Francesco, Steele, Andrew J, Cross, Jennifer, Mackenzie, Lloyd, Klener, Pavel, Packham, Graham

“…PI3K signaling is a common feature of B-cell neoplasms, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), and PI3K…”
Get full text

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53 by Williamson, Chris T., Kubota, Eiji, Hamill, Jeffrey D., Klimowicz, Alexander, Ye, Ruiqiong, Muzik, Huong, Dean, Michelle, Tu, LiRen, Gilley, David, Magliocco, Anthony M., McKay, Bruce C., Bebb, D. Gwyn, Lees‐Miller, Susan P.

“…Poly‐ADP ribose polymerase (PARP) inhibitors have shown promise in the treatment of human malignancies characterized by deficiencies in the DNA damage repair…”
Get full text

Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC by Petersen, Lars F, Klimowicz, Alexander C, Otsuka, Shannon, Elegbede, Anifat A, Petrillo, Stephanie K, Williamson, Tyler, Williamson, Chris T, Konno, Mie, Lees-Miller, Susan P, Hao, Desiree, Morris, Don, Magliocco, Anthony M, Bebb, D Gwyn

“…Ataxia-telangiectasia mutated (ATM) is critical in maintaining genomic integrity. In response to DNA double-strand breaks, ATM phosphorylates downstream…”
Get full text

DNA-dependent SUMO modification of PARP-1 by Zilio, Nicola, Williamson, Chris T., Eustermann, Sebastian, Shah, Rajvee, West, Stephen C., Neuhaus, David, Ulrich, Helle D.

“…•We examine the sumoylation of PARP-1 in response to different DNA ligands.•We characterise the dynamics of the PARP-1 SUMO conjugate by NMR.•Sumoylation of…”
Get full text

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness by Holme, Harriett, Gulati, Aditi, Brough, Rachel, Fleuren, Emmy D. G., Bajrami, Ilirjana, Campbell, James, Chong, Irene Y., Costa-Cabral, Sara, Elliott, Richard, Fenton, Tim, Frankum, Jessica, Jones, Samuel E., Menon, Malini, Miller, Rowan, Pemberton, Helen N., Postel-Vinay, Sophie, Rafiq, Rumana, Selfe, Joanna L., von Kriegsheim, Alex, Munoz, Amaya Garcia, Rodriguez, Javier, Shipley, Janet, van der Graaf, Winette T. A., Williamson, Chris T., Ryan, Colm J., Pettitt, Stephen, Ashworth, Alan, Strauss, Sandra J., Lord, Christopher J.

“…Osteosarcoma (OS) is an aggressive sarcoma, where novel treatment approaches are required. Genomic studies suggest that a subset of OS, including OS tumour…”
Get full text

Mo1930 ATM and P53 Expression Level Correlate With Sensitivity to Olaparib in Gastric Cancer by Kubota, Eiji, Williamson, Chris T, Lees-Miller, Susan P, Bebb, Gwyn

Get full text

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness by Holme, Harriett, Gulati, Aditi, Brough, Rachel, Fleuren, Emmy D. G., Bajrami, Ilirjana, Campbell, James, Chong, Irene Y., Costa-Cabral, Sara, Elliott, Richard, Fenton, Tim, Frankum, Jessica, Jones, Samuel E., Menon, Malini, Miller, Rowan, Pemberton, Helen N., Postel-Vinay, Sophie, Rafiq, Rumana, Selfe, Joanna L., von Kriegsheim, Alex, Munoz, Amaya Garcia, Rodriguez, Javier, Shipley, Janet, van der Graaf, Winette T. A., Williamson, Chris T., Ryan, Colm J., Pettitt, Stephen, Ashworth, Alan, Strauss, Sandra J., Lord, Christopher J.

“…A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper…”
Get full text

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer by Mateo, Joaquin, Carreira, Suzanne, Sandhu, Shahneen, Miranda, Susana, Mossop, Helen, Perez-Lopez, Raquel, Nava Rodrigues, Daniel, Robinson, Dan, Omlin, Aurelius, Tunariu, Nina, Boysen, Gunther, Porta, Nuria, Flohr, Penny, Gillman, Alexa, Figueiredo, Ines, Paulding, Claire, Seed, George, Jain, Suneil, Ralph, Christy, Protheroe, Andrew, Hussain, Syed, Jones, Robert, Elliott, Tony, McGovern, Ursula, Bianchini, Diletta, Goodall, Jane, Zafeiriou, Zafeiris, Williamson, Chris T, Ferraldeschi, Roberta, Riisnaes, Ruth, Ebbs, Bernardette, Fowler, Gemma, Roda, Desamparados, Yuan, Wei, Wu, Yi-Mi, Cao, Xuhong, Brough, Rachel, Pemberton, Helen, A’Hern, Roger, Swain, Amanda, Kunju, Lakshmi P, Eeles, Rosalind, Attard, Gerhardt, Lord, Christopher J, Ashworth, Alan, Rubin, Mark A, Knudsen, Karen E, Feng, Felix Y, Chinnaiyan, Arul M, Hall, Emma, de Bono, Johann S

“…Fourteen of 16 patients with metastatic, castration-resistant prostate cancer and genetic defects in repair of DNA damage had a response to the PARP inhibitor…”
Get full text

Abstract NTOC-093: SYNTHETIC LETHAL APPROACHES TO TARGET ARID1A DEFICIENT OVARIAN CANCERS by Khalique, Saira, Williamson, Chris T., Pemberton, Helen, Wai, Patty T., Menon, Malini, Brough, Rachel, Leonidou, Andri, Peck, Barrie, Banerjee, Susana, Natrajan, Rachael C., Lord, Christopher J.

“…Abstract Epithelial ovarian cancer (EOC) remains the most lethal gynaecological malignancy in the Western world. Ovarian clear cell carcinoma (OCCC), a…”
Get full text

ATM-deficiency sensitizes Mantle Cell Lymphoma cells to PARP-1 inhibitors by Williamson, Chris T., Muzik, Huong, Turhan, Ali G., Zamò, Alberto, O’Connor, Mark J., Bebb, D. Gwyn, Lees-Miller, Susan P.

“…Poly-ADP ribose polymerase-1 (PARP-1) inhibition is toxic to cells with mutations in the breast and ovarian cancer susceptibility genes BRCA1 or BRCA2, a…”
Get full text